Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384573 · ClinicalTrials.gov registry record · Phase 3
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT06384573: Active Phase 3 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.
NCT06384573 is a Phase 3 study of Dementia and Alzheimers Disease that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 40 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384573, a Phase 3 study of Dementia and Alzheimers Disease, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Conditions Studied
Interventions
- DRUG lecanemab
Study Locations (6)
Alabama
- University of Alabama in Birmingham - Birmingham
Indiana
- Indiana University School of Medicine - Indianapolis
Missouri
- Washington University in St. Louis - St Louis
Washington
- University of Washington - Seattle
New South Wales
- Neuroscience Research Australia - Randwick
Greater London
- The National Hospital for Neurology and Neurosurgery - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2030-06 |
| Phase | Phase 3 |
What the registry record for NCT06384573 still lists
NCT06384573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which lecanemab is the first listed.
NCT06384573 lists 6 locations in 6 states (Alabama, Indiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT06384573 about?
NCT06384573 is a clinical study titled "DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease". This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to exter...
What is the current status of trial NCT06384573?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2024-06-10. Estimated completion is 2030-06.
What conditions does trial NCT06384573 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease, Alzheimers Disease, Familial.
What interventions are being tested in trial NCT06384573?
The interventions under investigation include: lecanemab (DRUG).
Who is sponsoring clinical trial NCT06384573?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384573 being conducted?
This trial has 6 study locations across Alabama, Indiana, Missouri, Washington, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384573's enrollment target sits among peer trials
40 161st of 199 higher than 36 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
Escitalopram for Agitation in Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Preventing Cognitive Decline With Alternative Therapies
COMPLETED · Phase 3
-
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
COMPLETED · Phase 3
-
High Intensity Light Therapy in Alzheimer's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI